Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal for immunotherapy of cancer 2019-11, Vol.7 (1), p.285-285, Article 285
Hauptverfasser: Florou, Vaia, Rosenberg, Andrew E., Wieder, Eric, Komanduri, Krishna V., Kolonias, Despina, Uduman, Mohamed, Castle, John C., Buell, Jennifer S., Trent, Jonathan C., Wilky, Breelyn A.
Format: Artikel
Sprache:eng
Schlagworte:
Angiosarcoma
Antibodies
Correction
Immunoglobulin G
Ipilimumab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-019-0792-9